Longevity AI Hub

Clinical Milestones

• 🔥 Insilico Phase I Start: Insilico completes first-in-human dosing in Phase I trial of its AI-designed NLRP3 inhibitor...

Three angles reveal the current state of longevity research:

• Longevity Escape Velocity frames aging as a race science might win through geroscience,...

Insilico Medicine reached first-in-human dosing for its AI-designed NLRP3 inhibitor ISM8969 in Phase I trials, validating AI-driven discovery for targeting inflammation pathways central to aging and age-related diseases.

Longevity Funding Momentum

• 🔥 Gero Secures $17M: Singapore/San Francisco-based Gero raised $17M (total equity $34M) to advance AI-driven,...

This 57-minute podcast serves as a practical intro to venture capital moving into longevity, spotlighting funds that back early-stage biotech founders targeting human healthspan.

Gero just closed $17M more, reaching $34M total equity to train AI on 10M+ records and model aging as measurable physics.

CEO Peter Fedichev argues...

AI Tools for Longevity Research

• 🔥 Latent Labs AI Platform: Latent Labs' AI agents compress drug design timelines from 18 months to one month,...

Leading experts tackle Alzheimer's through distinct longevity lenses.

• Diagnostics emphasis: Dr. Gary Small details amyloid and tau assays, PET...

Bay Area labs are deploying AI to pinpoint why some people stay healthy into their 90s while others face earlier disease.

• Everlab raised $65M to...

Cenegenics pioneered proactive longevity care years before modern biohacking, using concierge biomarker tracking, epigenetics, and advanced...

AI models now compress 18-month antibody design timelines to one month, with agents reducing weeks of expert work to an afternoon. Founded by former...

Machine learning models are rapidly expanding aging biomarker prediction.

• Metabolomics-driven ensembles enable early osteoporosis forecasting and...

Elysium Health's Creatine+ launch shows supplements evolving from sports nutrition into evidence-based tools for healthy aging and healthspan.

-...

A specific variant in the CGAS gene, identified in Dutch long-lived families, appears to reduce harmful inflammation while preserving the body's...

Women undergo stronger inflammatory immune remodeling with age, boosting infection defense yet driving 80% of autoimmune cases, while men show subtler...

Tech billionaires are betting billions on cell reprogramming to reverse aging, but past longevity approaches have largely failed in the clinic.

-...

AI Platforms Validating Longevity Targets

• 🔥 Eli Lilly AI Bet: Eli Lilly committed $2.75B to AI-identified anti-aging drug candidates, with a...

AI tools are speeding anti-aging drug discovery, yet access remains a core question.

• Eli Lilly commits $2.75B to AI-driven anti-aging research,...

A scalable AI-guided multi-omic framework now pinpoints causal, repurposable therapeutic targets for aging and age-related diseases, directly accelerating drug development pipelines.

A Mass General Brigham study shows AI can assess thymus health from routine CT scans, linking it directly to longevity, heart disease, and cancer risk. This positions the often-overlooked organ as a practical new biomarker for aging assessment.